Premature LH surge ‐ Donor oocytes ‐ Normoresponders ‐ Early phase stimulation protocol ‐ Fresh embryo transfer · assisted reproduction technology cycles
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
Clinical improvement D60 or above · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether clazakizumab changes clinical improvement D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether clazakizumab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
Clinical improvement D60 or above · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether tociliuzumab changes clinical improvement D60 or moref compared with standard care/placebo (very low certainty).
1 finding from 1 review
Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether siltuximab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether levilimab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
Tociliuzumab showed no clear difference in all‐cause mortality D60 or more compared with standard care/placebo (low certainty).
1 finding from 1 review
Clinical improvement D60 or above · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes clinical improvement D60 or moree compared with standard care/placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Finding 8. Patients, caregivers, and healthcare providers called for more training in the context of in‐person home‐based rehabilitation.
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Intervention not reported
Finding 12. Patients, caregivers, healthcare providers and other stakeholders regarded telerehabilitation as an opportunity to make rehabilitation services more accessible.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive and educational outcomes in children more than five years old · postoperative pain in preterm and term infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive and educational outcomes in children more than five years old · postoperative pain in preterm and term infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive and educational outcomes in children more than five years old · postoperative pain in preterm and term infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive and educational outcomes in children more than five years old ‐ not reported · postoperative pain in neonates
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive and educational outcomes in children more than five years old ‐ not reported · postoperative pain in neonates
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found